跳至主要内容
临床试验/NCT02032147
NCT02032147已完成不适用

Treatment of Cerebral Radiation Necrosis (CRN) With Nerve Growth Factor (NGF)

Fudan University1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2009年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
30
试验地点
1
主要终点
efficacy of using NGF for treating CRN

研究概览

简要总结

Cerebral radiation necrosis (CRN) is a well-documented late complication of radiation therapy for cancers, and may have a devastating effect on the patient's quality of life (QOL). However,CRN was once regarded as a progressive and irreversible disease, no standard therapy has been suggested for CRN. In our clinical practice, we have used nerve growth factor(NGF) to treat CRN, and found that GM1 can successfully reverse CRN. A case report has been published in Journal of Clinical Oncology (JCO) in 2011. So we carried out this prospective study to test the efficacy of NGF for CRN.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The necrotic mass shown on MRI must be measured in two dimensions. No local or regional recurrence, no distant metastasis. Karnofsky performance status of at least 70 and were supposed to live more than 6 months.

排除标准

  • CRN combined with local or regional relapse, or with distant metastasis.
  • CRN combined with other cerebrovascular disease.
  • CRN combined with the second primary malignancy.
  • CRN without neurologic symptoms or signs.
  • CRN combined with diabetes.
  • CRN patients that were supposed to live less than 6 months.

研究组 & 干预措施

NGF group

This group will be treated with NGF 18u daily for 60 days.

干预措施: NGF group (Drug)

结局指标

主要结局

efficacy of using NGF for treating CRN

时间窗: 6-8 months

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Fan Ming

MD,PhD

Fudan University

研究点 (1)

Loading locations...

相似试验